An observational study in Squamous Cell Carcinoma and DaRT Treated Patients, sponsored by Alpha Tau Medical LTD.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by Alpha Tau Medical LTD. · Observational
Evaluation of long-term efficacy outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response.
Medical records of patients that previously underwent the Alpha DaRT treatment will be reviewed by an authorized staff member.
Evaluation of long-term outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response. These outcomes include:
Efficacy -
1,779 studies on the registry are indexed under Carcinoma, Squamous Cell; 409 are open to participants now.
This study's enrollment of 33 is below the median of 100 across 271 observational studies indexed under Carcinoma, Squamous Cell.
Browse Carcinoma, Squamous Cell studies →Alpha Tau Medical LTD. is the lead sponsor of 29 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The medical records of patients previously treated with Alpha DaRT as part of the completed clinical trial "CTP-SCC-00" will be accessed to follow up with their status, if available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None.
Progression Free Survival (PFS)
Time from DaRT insertion to disease progression (according to RECIST V1.1) or death, whichever occurs first
Time frame: Up to 60 months following DaRT insertion
Adverse Events (AE)
Assessment of late onset of Alpha DaRT related AE
Time frame: Up to 60 months following DaRT insertion
Duration of Response
Time from partial or complete response to the first disease progression according to RECIST V1.1
Time frame: Up to 60 months following DaRT insertion
Overall Survival (OS)
Time from DaRT insertion to death
Time frame: Up to 60 months following DaRT insertion
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.